Clinical Trial

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.
Protocol Amendment History 5 changes
notable Trial sites expanded: 34 -> 39 locations 2026-08-11
notable Trial sites expanded: 31 -> 34 locations 2026-07-10
notable Trial sites expanded: 27 -> 31 locations 2026-05-28
critical Recruitment opened 2026-04-23
notable Trial sites expanded: 0 -> 27 locations 2026-04-23
Trial Details
NCT Number NCT07474792
Lead Sponsor Oruka Therapeutics, Inc.
Conditions Plaque Psoriasis
Enrollment 160 participants
Start Date 2026-03-19
Primary Completion 2027-10 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-10